Packaged Foods
Compare Stocks
2 / 10Stock Comparison
DAR vs BIOX
Revenue, margins, valuation, and 5-year total return — side by side.
Agricultural Inputs
DAR vs BIOX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Packaged Foods | Agricultural Inputs |
| Market Cap | $9.88B | $30M |
| Revenue (TTM) | $6.14B | $318M |
| Net Income (TTM) | $63M | $-53M |
| Gross Margin | 15.7% | 39.1% |
| Operating Margin | 6.4% | 0.2% |
| Forward P/E | 15.1x | — |
| Total Debt | $4.16B | $277M |
| Cash & Equiv. | $89M | $33M |
DAR vs BIOX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Darling Ingredients… (DAR) | 100 | 267.1 | +167.1% |
| Bioceres Crop Solut… (BIOX) | 100 | 7.1 | -92.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: DAR vs BIOX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
DAR carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 1 yrs, beta 0.72
- Rev growth 7.4%, EPS growth -77.5%, 3Y rev CAGR -2.0%
- 339.4% 10Y total return vs BIOX's -95.1%
BIOX is the clearest fit if your priority is value.
- Better valuation composite
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 7.4% revenue growth vs BIOX's -28.3% | |
| Value | Better valuation composite | |
| Quality / Margins | 1.0% margin vs BIOX's -16.6% | |
| Stability / Safety | Beta 0.72 vs BIOX's 1.94, lower leverage | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +88.8% vs BIOX's -88.5% | |
| Efficiency (ROA) | 0.6% ROA vs BIOX's -6.7%, ROIC 3.4% vs -0.5% |
DAR vs BIOX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
DAR vs BIOX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
Evenly matched — DAR and BIOX each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
DAR is the larger business by revenue, generating $6.1B annually — 19.3x BIOX's $318M. DAR is the more profitable business, keeping 1.0% of every revenue dollar as net income compared to BIOX's -16.6%. On growth, DAR holds the edge at +21.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $6.1B | $318M |
| EBITDAEarnings before interest/tax | $901M | $21M |
| Net IncomeAfter-tax profit | $63M | -$53M |
| Free Cash FlowCash after capex | $679M | $37M |
| Gross MarginGross profit ÷ Revenue | +15.7% | +39.1% |
| Operating MarginEBIT ÷ Revenue | +6.4% | +0.2% |
| Net MarginNet income ÷ Revenue | +1.0% | -16.6% |
| FCF MarginFCF ÷ Revenue | +11.1% | +11.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | +21.2% | -16.4% |
| EPS Growth (YoY)Latest quarter vs prior year | -42.9% | -37.3% |
Valuation Metrics
BIOX leads this category, winning 4 of 5 comparable metrics.
Valuation Metrics
On an enterprise value basis, DAR's 15.4x EV/EBITDA is more attractive than BIOX's 20.0x.
| Metric | ||
|---|---|---|
| Market CapShares × price | $9.9B | $30M |
| Enterprise ValueMkt cap + debt − cash | $14.0B | $274M |
| Trailing P/EPrice ÷ TTM EPS | 159.64x | -0.58x |
| Forward P/EPrice ÷ next-FY EPS est. | 15.09x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 15.43x | 20.01x |
| Price / SalesMarket cap ÷ Revenue | 1.61x | 0.09x |
| Price / BookPrice ÷ Book value/share | 2.07x | 0.10x |
| Price / FCFMarket cap ÷ FCF | 14.55x | 0.85x |
Profitability & Efficiency
DAR leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
DAR delivers a 1.3% return on equity — every $100 of shareholder capital generates $1 in annual profit, vs $-17 for BIOX. DAR carries lower financial leverage with a 0.87x debt-to-equity ratio, signaling a more conservative balance sheet compared to BIOX's 0.94x. On the Piotroski fundamental quality scale (0–9), DAR scores 7/9 vs BIOX's 3/9, reflecting strong financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | +1.3% | -16.7% |
| ROA (TTM)Return on assets | +0.6% | -6.7% |
| ROICReturn on invested capital | +3.4% | -0.5% |
| ROCEReturn on capital employed | +4.3% | -0.8% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 3 |
| Debt / EquityFinancial leverage | 0.87x | 0.94x |
| Net DebtTotal debt minus cash | $4.1B | $244M |
| Cash & Equiv.Liquid assets | $89M | $33M |
| Total DebtShort + long-term debt | $4.2B | $277M |
| Interest CoverageEBIT ÷ Interest expense | 1.76x | -0.07x |
Total Returns (Dividends Reinvested)
DAR leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DAR five years ago would be worth $8,563 today (with dividends reinvested), compared to $317 for BIOX. Over the past 12 months, DAR leads with a +88.8% total return vs BIOX's -88.5%. The 3-year compound annual growth rate (CAGR) favors DAR at 2.6% vs BIOX's -64.0% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +65.4% | -65.0% |
| 1-Year ReturnPast 12 months | +88.8% | -88.5% |
| 3-Year ReturnCumulative with dividends | +8.1% | -95.3% |
| 5-Year ReturnCumulative with dividends | -14.4% | -96.8% |
| 10-Year ReturnCumulative with dividends | +339.4% | -95.1% |
| CAGR (3Y)Annualised 3-year return | +2.6% | -64.0% |
Risk & Volatility
DAR leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
DAR is the less volatile stock with a 0.72 beta — it tends to amplify market swings less than BIOX's 1.94 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DAR currently trades 94.3% from its 52-week high vs BIOX's 9.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.72x | 1.94x |
| 52-Week HighHighest price in past year | $66.02 | $5.18 |
| 52-Week LowLowest price in past year | $29.15 | $0.35 |
| % of 52W HighCurrent price vs 52-week peak | +94.3% | +9.1% |
| RSI (14)Momentum oscillator 0–100 | 58.5 | 44.6 |
| Avg Volume (50D)Average daily shares traded | 2.8M | 804K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — |
| Price TargetConsensus 12-month target | $62.86 | — |
| # AnalystsCovering analysts | 25 | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.4% | +3.1% |
DAR leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). BIOX leads in 1 (Valuation Metrics). 1 tied.
DAR vs BIOX: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is DAR or BIOX a better buy right now?
For growth investors, Darling Ingredients Inc.
(DAR) is the stronger pick with 7. 4% revenue growth year-over-year, versus -28. 3% for Bioceres Crop Solutions Corp. (BIOX). Darling Ingredients Inc. (DAR) offers the better valuation at 159. 6x trailing P/E (15. 1x forward), making it the more compelling value choice. Analysts rate Darling Ingredients Inc. (DAR) a "Buy" — based on 25 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — DAR or BIOX?
Over the past 5 years, Darling Ingredients Inc.
(DAR) delivered a total return of -14. 4%, compared to -96. 8% for Bioceres Crop Solutions Corp. (BIOX). Over 10 years, the gap is even starker: DAR returned +339. 4% versus BIOX's -95. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — DAR or BIOX?
By beta (market sensitivity over 5 years), Darling Ingredients Inc.
(DAR) is the lower-risk stock at 0. 72β versus Bioceres Crop Solutions Corp. 's 1. 94β — meaning BIOX is approximately 170% more volatile than DAR relative to the S&P 500. On balance sheet safety, Darling Ingredients Inc. (DAR) carries a lower debt/equity ratio of 87% versus 94% for Bioceres Crop Solutions Corp. — giving it more financial flexibility in a downturn.
04Which is growing faster — DAR or BIOX?
By revenue growth (latest reported year), Darling Ingredients Inc.
(DAR) is pulling ahead at 7. 4% versus -28. 3% for Bioceres Crop Solutions Corp. (BIOX). On earnings-per-share growth, the picture is similar: Darling Ingredients Inc. grew EPS -77. 5% year-over-year, compared to -1704. 7% for Bioceres Crop Solutions Corp.. Over a 3-year CAGR, BIOX leads at 0. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — DAR or BIOX?
Darling Ingredients Inc.
(DAR) is the more profitable company, earning 1. 0% net margin versus -15. 5% for Bioceres Crop Solutions Corp. — meaning it keeps 1. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DAR leads at 6. 4% versus -1. 1% for BIOX. At the gross margin level — before operating expenses — BIOX leads at 39. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — DAR or BIOX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is DAR or BIOX better for a retirement portfolio?
For long-horizon retirement investors, Darling Ingredients Inc.
(DAR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 72), +339. 4% 10Y return). Bioceres Crop Solutions Corp. (BIOX) carries a higher beta of 1. 94 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DAR: +339. 4%, BIOX: -95. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between DAR and BIOX?
These companies operate in different sectors (DAR (Consumer Defensive) and BIOX (Basic Materials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.